Indications |
Intravenous Induction of anaesthesia Adult: 1-4.5 mg/kg as IV inj. Surgical anaesthesia is produced within 30 sec of the end of inj. Usual dose to produce 5-10 minutes of anaesthesia: 2 mg/kg over 60 seconds. Alternatively, 1-2 mg/kg infused at 0.5 mg/kg/minute; may use with diazepam to prevent emergence reactions. Child: 1-4.5 mg/kg as IV Inj. Surgical anaesthesia is produced within 30 sec of the end of inj and lasts for 5-10 min if 2 mg/kg is given over 60 sec. Alternatively, 0.5-2 mg/kg as IV infusion. Maintenance: Achieve with 10-45 mcg/kg/min; titrate infusion rate according to response. Intramuscular Induction of anaesthesia Adult: 6.5-13 mg/kg. Usual dose to produce 12-25 minutes of anesthesia: 10 mg/kg. Incompatibility: May form precipitates with barbiturates; do not inject in the same syringe. |
Contraindications |
Hypertension, history of cerebrovascular accident. Eye injury, raised ocular and intracranial pressure. Psychotic disorders. |
Warnings / Precautions |
Minimise verbal and tactile stimulation during recovery period. Chronic alcoholic and alcohol-intoxicated patients. Preanaesthetic elevated CSF pressure. Dependence and tolerance may develop. May impair ability to drive or operate machinery. Monitor cardiac function in patients with hypertension or cardiac decompensation. Pregnancy and lactation. |
Adverse Reactions |
Emergence reactions e.g. vivid dreams, hallucinations, confusion, irrational behaviour. Increased muscle tone sometimes resembling seizures. Temporary hypertension and tachycardia. Hypotension, bradycardia, arrhythmias. Respiratory depression, apnoea, laryngospasm, diplopia, nystagmus, nausea, vomiting, lachrymation, hypersalivation, raised intraocular and CSF pressure, skin rash and pain at inj site. |
Drug Interactions |
May increase effects of nondepolarising muscle relaxants. May reduce hypnotic effect of thiopental. Prolonged recovery time with barbiturates/narcotics. Reduced cardiac output, BP and pulse rate with halothane. Increased risk of hypertension and tachycardia with thyroid hormones. Seizures and tachycardia may occur when used with theophyllines. See Below for More ketamine Drug Interactions |
Mechanism of Actions |
Ketamine has a direct action on the cortex and limbic system. It produces a cataleptic-like state wherein the patient is withdrawn from the surrounding environment. Distribution: Crosses the placenta. Metabolism: Hepatic biotransformation to norketamine. Other metabolic pathways include hydroxylation of the cyclohexone ring and conjugation with glucuronic acid. Excretion: Via urine (as metabolites); 2.5 hr (beta phase half-life). |
Storage Conditions |
Intramuscular: Store at 15-30°C (59-86°F). Intravenous: Store at 15-30°C (59-86°F). |
ATC Classification |
N01AX03 - ketamine ; Belongs to the class of other general anesthetics. |
Storage |
Intramuscular: Store at 15-30°C (59-86°F). Intravenous: Store at 15-30°C (59-86°F). |
Available As |
|
Ketamine
Post Review about Ketamine Click here to cancel reply.
Ketamine Containing Brands
Ketamine is used in following diseases
Drug - Drug Interactions of Ketamine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.